Premium Income Corporation Announces Successful Overnight Offering Of Preferred Shares

Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) — (TSX: PIC.PR.A) – Premium Income Corporation (the “Fund”) is pleased to announce a successful overnight treasury offering of 4,350,000 Preferred Shares. Gross proceeds of the offering are expected to be $65,250,000. The offering is […]

SEALSQ Organizes “The Day After Tomorrow: IoT Security in the Post-Quantum Age” Webinar

(NASDAQ:LAES),(NASDAQ:LAESV), Geneva, Switzerland, Oct. 30, 2024 (GLOBE NEWSWIRE) — SEALSQ Organizes “The Day After Tomorrow: IoT Security in the Post-Quantum Age” Webinar Webinar starts at 11:00 am ET (4:00 pm CET) Join the webinar via https://hubs.li/Q02VFxJg0 SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum

Premium Income Corporation Announces Successful Overnight Offering Of Preferred Shares

(TSX:PIC.PR.A),(TSX: PIC-A), Not for distribution to U.S. newswire services or for dissemination in the United States. TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) — (TSX: PIC.PR.A) – Premium Income Corporation (the “Fund”) is pleased to announce a successful overnight treasury offering of 4,350,000 Preferred Shares. Gross proceeds of the offering are expected to be $65,250,000. The

RAISE Summit 2025 to Shape the Future of AI Confirmed for July in Paris

PARIS, Oct. 30, 2024 (GLOBE NEWSWIRE) — RAISE Summit, the leading conference for the AI industry, has announced its 2025 event. Set to take place on July 8-9 in Paris, RAISE 2025 will bring together thousands of delegates to explore the future of artificial intelligence and meet the visionaries shaping this transformative technology. Poised to

RAISE Summit 2025 to Shape the Future of AI Confirmed for July in Paris

PARIS, Oct. 30, 2024 (GLOBE NEWSWIRE) — RAISE Summit, the leading conference for the AI industry, has announced its 2025 event. Set to take place on July 8-9 in Paris, RAISE 2025 will bring together thousands of delegates to explore the future of artificial intelligence and meet the visionaries shaping this transformative technology. Poised to

Yesway Pledges Support to Communities Affected by the Flooding in Roswell, New Mexico

Customers and supplier partners are invited to join and donateat all Yesway and Allsup’s store locations in support of Roswell Strong Yesway, one of the country’s fastest growing convenience store chains, today announced its commitment to donate $100,000 to the Community Foundation of Southern New Mexico (CFSNM) in support of the Roswell, New Mexico community

Yesway Pledges Support to Communities Affected by the Flooding in Roswell, New Mexico

Customers and supplier partners are invited to join and donateat all Yesway and Allsup's store locations in support of Roswell Strong Yesway, one of the country's fastest growing convenience store chains, today announced its commitment to donate $100,000 to the Community Foundation of Southern New Mexico (CFSNM) in support of the Roswell, New Mexico community

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster presentation WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

(NASDAQ:REPL), Late-breaking abstract featuring IGNYTE clinical trial data, including subgroup and initial biomarker analyses, selected for oral presentation Data from ARTACUS clinical trial of RP1 monotherapy in solid organ transplant patients with advanced cutaneous malignancies selected for encore poster presentation WOBURN, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical

Scroll to Top